ARS Pharmaceuticals, Inc.
SPRY · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Mar 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $84.3M | $89.2M | −5.5% |
| Operating income | −$179M | −$3.08M | −5,726% |
| Net income | −$171M | $8.00M |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 5, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $37.7M | $32.5M | +16.0% |
| Operating income | −$34.2M | −$53.2M | +35.7% |
| Net income | −$35.6M | −$51.2M | +30.5% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was ARS Pharmaceuticals's revenue in FY2025?
- $84.3M in FY2025 (Fiscal year ended Dec 31, 2025), −5.5% vs $89.2M a year earlier, per its 10-K filed Mar 2026.
- Was ARS Pharmaceuticals profitable in FY2025?
- No: net income was −$171M and operating income −$179M in FY2025.
- What was ARS Pharmaceuticals's revenue in Q3 2026?
- $37.7M (+16.0% vs a year earlier), per its Form 10-Q filed Nov 5, 2026.